Feature

Stopping anti-TNF drugs in PsA has high rebound risk

Publish date: October 26, 2017

 

FROM JOURNAL OF RHEUMATOLOGY

Pages

Recommended Reading

Launch of adalimumab biosimilar Amjevita postponed
MDedge Dermatology
TNF inhibitors associated with fewer side effects than methotrexate in children with psoriasis
MDedge Dermatology
Ixekizumab has profound impact on genital psoriasis
MDedge Dermatology
Genital psoriasis is the worst: Patients sound off
MDedge Dermatology
Biologic approved for moderate to severe psoriasis in adolescents
MDedge Dermatology
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
MDedge Dermatology
High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar
MDedge Dermatology
Psoriasis: Biologics bring potential for long-term remission off treatment
MDedge Dermatology
Golimumab earns new FDA approvals
MDedge Dermatology
Biosimilars poised to save $54 billion over the next decade
MDedge Dermatology

Related Articles